Displaying drugs 11001 - 11025 of 11910 in total
Cellspan Esophageal Implant
The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.
Investigational
Matched Description: … ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a …
Epicept NP-1
EpiCept NP-1 is a prescription topical analgesic cream designed to provide effective, long-term relief from the pain of peripheral neuropathies. Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system. The peripheral nervous system includes nerves that run from the brain and spinal cord...
Investigational
Matched Description: … EpiCept NP-1 Cream is a patented formulation containing two FDA-approved drugs, amitriptyline (a widely-used ... EpiCept NP-1 is a prescription topical analgesic cream designed to provide effective, long-term relief …
Siagoside
Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and repair. Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to...
Investigational
Matched Description: … It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a role in ... Treatment results in a 52% decrease in mortality 48 hours after the induction of ischemia in gerbils …
Distigmine
Distigmine is a parasympathomimetic agent with a longer duration of action and enhanced drug accumulation compared to DB00545 and DB01400. It is an anticholinergic drug and long-acting reversible carbamate cholinesterase inhibitor that binds directly and competitively to the agonist binding sites of muscurinic receptors. Distigmine is available in several countries...
Experimental
Matched Description: … Distigmine is a parasympathomimetic agent with a longer duration of action and enhanced drug accumulation ... Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction …
IRX-5183
Investigational
OM85
OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.
Investigational
Matched Description: … OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity …
INS 316
INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer. It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.
Investigational
VGV-1
VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.
Investigational
Matched Description: … VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral …
SLx-4090
SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.
Investigational
Matched Description: … SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment …
Mitemcinal
Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Investigational
Matched Description: … Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin …
β-Hydroxythiofentanyl
β-Hydroxythiofentanyl is an analgesic of the opioid class. This drug is an analog of fentanyl, a potent opioid.
Illicit
Matched Description: … This drug is an analog of fentanyl, a potent opioid. …
Icrucumab
Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
Investigational
Matched Description: … Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal …
MS-1819
MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose of MS1819-SD).
Investigational
Matched Description: … MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose …
GSK-2981278
GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis).
Investigational
Matched Description: … GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects …
Zagotenemab
Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).
Investigational
Matched Description: … Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants …
NM3086
NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.
Experimental
Matched Description: … NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being …
SAR422459
SAR422459 is a Lentiviral Vector Containing The Human Abca4 Gene that is currently being investigated to treat Stargardt disease.
Investigational
Matched Description: … SAR422459 is a Lentiviral Vector Containing The Human Abca4 Gene that is currently being investigated …
SEL-302
SEL-302 is a recombinant adeno-associated virus vector-based gene therapy expressing the methylmalonyl-CoA mutase (MMUT) transgene.
Investigational
Matched Description: … SEL-302 is a recombinant adeno-associated virus vector-based gene therapy expressing the methylmalonyl-CoA …
CTR-107
CTR-107 is a synthetic targeted growth factor. It is being investigated for the treatment of familial exudative vitreoretinopathy.
Investigational
Matched Description: … CTR-107 is a synthetic targeted growth factor. …
RC88
RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational
Matched Description: … RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated …
TAK-071
TAK-071 is under investigation in clinical trial NCT04334317 (A Study of TAK-071 in People With Parkinson Disease).
Investigational
Matched Description: … TAK-071 is under investigation in clinical trial NCT04334317 (A Study of TAK-071 in People With Parkinson …
PTC299
PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF...
Investigational
Matched Description: … PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular ... Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration …
Malacidin B
Malacidin B, along with DB14051, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. While structurally similar to other macrocycle drugs like DB00080 and DB06087, Malacidin B...
Experimental
Matched Description: … Malacidin B, along with [DB14051], is a member of a class of chemicals made by bacteria found in soil …
BNT162b3
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. ... As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). …
XL281
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which...
Investigational
Matched Description: … XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway ... XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated …
Displaying drugs 11001 - 11025 of 11910 in total